$PFE

Buckley Mortimer J purchased $960K of PFE

Buckley Mortimer J purchased 37,632 shares of PFIZER INC (PFE) at $25.52 ($0.96M total) on 2026-08-05.

Original reporting
SEC EDGAR · Buckley Mortimer J
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PFE
Neutral
medium confidence
Mentioned
$PFE
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFENeutralLow
01

Why it matters

A director open-market purchase is incremental sentiment information, not a new fundamental driver.

02

Market read

Traders may note the insider buy, but there is no accompanying guidance, legal, regulatory, or operational update.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not reveal intent, timing constraints, or whether the purchase is meaningful versus prior activity.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-05, after-hours/late session disclosure

Background

The article is a SEC Form 4 insider transaction disclosure for Pfizer Inc.

Company-level read

Ticker impact

$PFENeutralMedium confidence
Context

Pfizer director Buckley Mortimer J bought 37,632 shares in an open-market transaction on 2026-08-05 for about $960K.

Expected impact

Likely limited near-term impact; may modestly support sentiment but is usually not trade-driving alone.

Evidence & confidence

Form 4 insider purchases can be read as confidence signals, yet the filing provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider activity without broader industry news.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine, tax-related, or part of personal liquidity planning, so the signal may be weak.

Key entities

  • Pfizer Inc

    Subject of the Form 4 insider transaction disclosure.

  • Buckley Mortimer J

    Director who purchased 37,632 shares on 2026-08-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PFEMedAI 8/10

Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

Pfizer (PFE) stock has declined 19.19% over five years, resulting in a 6% dividend yield. The company paid $9.77 billion in dividends in 2025, with a thin cash cushion. CEO Albert Bourla assured dividend maintenance but ruled out near-term hikes. Q2 2026 adjusted EPS was $0.77, beating estimates, with full-year guidance of $2.80-$3.00.

$PFEHighAI 8/10

19 vaccine approved by US FDA

The US FDA approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for adults 65+ and high-risk individuals 5-64. The approval is based on clinical, real-world, and manufacturing data. The vaccine targets the XFG variant and will be available in the US from autumn 2026.

$MRNAMed

Updated COVID-19 vaccines are coming this fall. Will insurance cover them?

The FDA approved updated COVID-19 vaccines from Moderna, Pfizer, and Sanofi for the fall season. Health insurers, per AHIP, will cover these vaccines, as required by the Affordable Care Act. Uninsured individuals may access free vaccines through state or federal programs. The vaccines target specific high-risk groups, with recommendations from the AAFP and CDC.

$PFEHighAI 9/10

FDA Approves Updated COVID-19 Vaccines for 2026-2027

The FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax targeting the JN.1-lineage XFG variant. Approvals cover high-risk populations, including adults 65+ and those with underlying conditions. Pfizer and Moderna's mRNA vaccines and Novavax's protein-based vaccine are now authorized for distribution.